Ms. Mary Newman Mcmahon, PHD LICSW Psychologist Medicare: Not Enrolled in Medicare Practice Location: One Hospital Court, Bellows Falls, VT 05101 Phone: 802-463-3294 Fax: 802-463-1202 |
Dr. Kristen Elizabeth Hurd, PSY.D. Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 49 Village Sq, Bellows Falls, VT 05101 Phone: 802-649-2260 |
Barbara L Laney, LCSW Psychologist Medicare: Medicare Enrolled Practice Location: 1 Hospital Ct, Ste. 410, Bellows Falls, VT 05101 Phone: 802-463-3947 Fax: 802-463-1206 |
Ms. Margaret M Hannigan, LCMHC LADC Psychologist Medicare: Not Enrolled in Medicare Practice Location: One Hospital Court, Bellows Falls, VT 05101 Phone: 802-463-3294 Fax: 802-463-1202 |
Ms. Leona Phyllis Brown, LCMHC Psychologist - Group Psychotherapy Medicare: Medicare Enrolled Practice Location: 134 Rockingham Street, Bellows Falls, VT 05101 Phone: 802-463-1404 Fax: 802-463-4180 |
Dr. Donald Edward Sanborn Iii, PSY. D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 40 Atkinson St, Bellows Falls, VT 05101 Phone: 802-463-3481 |
News Archive
Abbott today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication.
A group of researchers led by scientists from the Virginia Bioinformatics Institute at Virginia Tech have developed a new technology that detects distinct genetic changes differentiating cancer patients from healthy individuals and could serve as a future cancer predisposition test.
Results of a clinical trial released today in STEM CELLS Translational Medicine indicate that a combination of stem cell therapy and educational intervention can significantly help children with autism spectrum disorder (ASD).
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, and Handok Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical company, today announced a collaboration for the development and commercialization of apaziquone in South Korea. Apaziquone is an antineoplastic agent currently being investigated for the treatment of non-muscle invasive bladder cancer by intravesical instillation.
› Verified 1 days ago